Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

Background. Most evidence regarding anticoagulation and COVID-19 refers to the hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission has not been well explored. We compared clinical outcomes and short-term prognosis between patients with and without prior OAC therapy who were hospitalized for COVID-19. Methods. Analysis of the whole cohort of the HOPE COVID-19 Registry which included patients discharged (deceased or alive) after hospital admission for COVID-19 in 9 countries. All-cause mortality was the primary endpoint. Study outcomes were compared after adjusting variables using propensity score matching (PSM) analyses. Results. 7698 patients were suitable for the present analysis (675 (8.8%) on OAC at admission: 427 (5.6%) on VKAs and 248 (3.2%) on DOACs). After PSM, 1276 patients were analyzed (638 with OAC; 638 without OAC), without significant differences regarding the risk of thromboembolic events (OR 1.11, 95% CI 0.59-2.08). The risk of clinically relevant bleeding (OR 3.04, 95% CI 1.92-4.83), as well as the risk of mortality (HR 1.22, 95% CI 1.01-1.47; log-rank p value = 0.041), was significantly increased in previous OAC users. Amongst patients on prior OAC only, there were no differences in the risk of clinically relevant bleeding, thromboembolic events, or mortality when comparing previous VKA or DOAC users, after PSM. Conclusion. Hospitalized COVID-19 patients on prior OAC therapy had a higher risk of mortality and worse clinical outcomes compared to patients without prior OAC therapy, even after adjusting for comorbidities using a PSM. There were no differences in clinical outcomes in patients previously taking VKAs or DOACs. This trial is registered with NCT04334291/EUPAS34399

Manual de procedimientos para el diseño y mecanización por medio de software del cálculo de materiales y mano de obra de proyectos telefonicos

El trabajo que a continuación se desarrolla les permitira conocer preliminarmente las generalidades, acerca del área de planta externa, su definición y la descripción de los elementos que la constituyen, el por que de suimportancia para la telefonía y para cualquier empresa o compañía dedicada al basto mundo de la telefonía . También se consideranlas obras que permiten establecer de forma física la interconección entre los abonados de una central telefonica, las cuales permiten que un abonado, de la misma zona; tambien permite la comunicación entre las centrales y estas a su ves entre entre sus abonados. El conocimiento de planta externa implica necesariamente que se deben conocer los materiales con los cuales se construyen las redes de la misma. Estos materiales se describeny a la vez se ilustran en un glosario de accesorios que se consideran como los más utilizados en proyectos telefonicos en nuestro país. La utilización de estos materiales depende en gran medida de la aceptación por parte de ANTEL, atendiendo a que dichos materiales estan sujetos a las normas internacionales ; ASTM, las cuales rigen las contrucciones de los mismos mediante pruebas que necesariamente se les practicán, para mantener un control de calidad

Caracterización y obtención de cepas mejoradas de hongos entomopatógenos.

IP 2251-12-330-95Incluye también Etapa 3.aislamientos de Beauveria bassiana de una coleccion de hongosentomopatogenos de Cenicafe / Beatriz Elena;Valdes Duque, Patricia Eugenia Velez Arango. -- En: Revista colombiana deentomologia. -- vol. 24, no. 1-2;(ene.-jun. 1998); p.61-66. -- ISSN 01200488 -- Analisis delavariabilidadgenetica del hongo entomopatogeno;Beauveria bassiana con marcadores RAPD / Ana Milena ValderramaF., Marco Aurelio Cristancho A., Bernardo;Chaves C. -- En: Revista colombiana de entomologia. -- vol. 26,no. 1-2 (ene.-jun. 2001); p. 25-29. -- ISSN;01200488 -- Estandarizacion de una metodologia para obtener cultivos monoesporicos del hongo Beauveria;bassiana / Maria Nancy Estrada V., Patricia E. Velez A., JuanCarlos LopezN. -- En: Cenicafe : revista del;Centro Nacional de Investigaciones de Cafe. -- vol. 48, no. 1(ene.-mar. 1997); p. 59-65. -- ISSN 01200488 --;detection of Beauvericin from the entomopathogenic fungus: Beauveria bassiana / J.W.V. Arboleda, F.B. Deldago;and A.J. Valencia. -- En: International Colloquium on Invertebrate Pathology and Microbial Control (ICIPMC),;Annual Meeting of the SIP, International Conference on BacillusThuringiensis (ICBt). (8, 25, 6 : 2002 Aug.;18-23) -- ARTICULO(S) EN REVISTA: Actividad enzimatica dehongosy su patogenicidad sobre Hypothenemus hampei;/ Fernando Delgado Blandon, Yamel Lopez Forero, Elsa MariaGiraldo Cardozo. -- En: Revista manejo integrado de;plagas. -- No. 60 (2001); p. 43-49 -- Actividad lipoliticay proteoliticade Beauveria bassiana y Metarhizium;anisopliae y su relacion con la patogenicidad sobre Hypothenemushampei (Coleoptera: Scolytidae) / Elsa Maria;Giraldo Cardozo ... [et al.]. -- En: Revista colombiana deentomologia. --vol. 27, no. 1-2 (ene.-jun. 2001);p. 61-65. -- ISSN 01200488 -- Caracterizacion de aislamientosdeBeauveriabassiana y Metarhizium anisopliae;de la coleccion de Cenicafe / Patricia E. Velez A... [et al.].-'- en: Revista colombiana de entomologia. --;vol. 25, no. 3-4 (jul.-dic. 1999); p. 191-207. -- ISSN 012488'-- Caracterizacion bioquimica cualitativa de;Colombiana de Entomologia, Socolen (28 : 2001 ago. 8-10 :Pereira, Colombia) -- [s.l. : s.n.], 2001 -- p. ; 28;cm. -- Avances en el estudio de la toxina beauvericina producidapor el hongo Beauveria bassiana patogenico a;Hypothenemus hampei (Ferrari) (Coleoptera: Scolytidae) / JorgeWilliam Arboleda V., Fernando Delgado B. -- En:;Congreso de la Sociedad Colombiana de Entomologia, Socolen(28:2001 ago.8-10 : Pereira, Colombia) -- [s.l.;: s.n.], 2001 -- p. ; 28 cm. -- Biologia de Phymastichus coffeaLasalle (Hymenoptera: Eulophidae);endoparasitoide de la broca del cafe, en tres altitudes diferentes de la zonacafetera colombiana / Fernando;Cantor R. ... [et al.]. -- En: Congreso de la Sociedad Colombiana de Entomologia, Socolen (28 : 2001 ago. 8-10;: Pereira, Colombia) -- [s.l. : s.n.], 2001 -- p. ; 28 cm.--Produccion de anticuerpos policlonales para;deteccion de Beauvericina del hongo entomopatogeno Beauverianabassiana /Jorge W. Arboleda V., Fernando;Delgado B., Arnubio Valencia J. -- En: Congreso de la SociedadColombianade Entomologia, Socolen. (29 : 2002;jul. 18-19 : Monteria, Colombia) -- [s.l. : s.n.], 2002 --p.;28 cm. --Polyclonal antibodies productions to;Caracterizacion de cultivos monoesporicos del hongo Beauveriabassiana / Maria Nancy Estrada Valencia,;Patricia Eugenia Velez Arango, Esther Cecilia Montoya Restrepo.'-- en: Cenicafe : revista del Centro Nacional;de Investigaciones de Cafe. -- vol. 48, no. 4 (oct.-dic. 1997);p. 217-224. -- ISSN 01200275 -- Esporulacion,;germinacion y patogenicidad de aislamientos monoesporicosde Beauveria bassiana / Maria Nancy Estrada Velez;... [et al.]. -- Cenicafe : revista del Centro Nacional deInvestigacionesde Cafe. -- vol. 50, no. 1;(ene.-mar. 1999); p. 5-23. -- ISSN 01200275 -- Caracterizacionenzimaticay patogenicidad de aislamientos de;Beauveria bassiana sobre la broca del cafe / Beatriz ElenaValdes D., Patricia Eugenia Velez Arango, Esther;Cecilia Montoya Restrepo. -- Cenicafe : revista del CentroNacional de Investigaciones de Cafe. -- vol. 50,;no. 2 (abr.-jun. 1999); p. 106-118. -- ISSN 01200275 -- Evaluacion en campo de un aislamiento de Beauveria;bassiana seleccionado por resistencia a la luz ultravioleta /Sandra Patricia Tobar H., Patricia Eugenia Velez;Arango, Esther Cecilia Montoya Restrepo. -- En: Revista del Centro Internacional de Investigacion de Cafe. --;01200275.;PONENCIA(S) EN CONGRESO: Transformacion de Beauveria bassianacon la proteina verde fluorescente y proteasas;de Metarhizium anisopliae / Carmenza E. Gongora B. -- En:Congreso de la Sociedad Colombiana de Entomologia,;Socolen (28 : 2001 ago. 8-10 : Pereira, Colombia) -- [s.l.: s.n.], 2001 -- p. ; 28 cm. -- Taller con;caficultores experimentadores para evaluar Beauveria bassianaenel control de Hypothenemus hampei (Ferrari);(Coleoptera: Scolytidae) / Francisco Javier Posada Florez...[et al.]. --En: Congreso de la Socieda

Libro de Proyectos Finales 2021 primer semestre

PregradoIngeniero CivilIngeniero de SistemasIngeniero ElectricistaIngeniero ElectrónicoIngeniero IndustrialIngeniero Mecánic

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Measurements of ttˉt\bar{t} differential cross-sections of highly boosted top quarks decaying to all-hadronic final states in pppp collisions at s=13 \sqrt{s}=13\, TeV using the ATLAS detector

Measurements are made of differential cross-sections of highly boosted pair-produced top quarks as a function of top-quark and $t\bar{t}$ system kinematic observables using proton--proton collisions at a center-of-mass energy of $\sqrt{s} = 13$ TeV. The data set corresponds to an integrated luminosity of $36.1$ fb$^{-1}$, recorded in 2015 and 2016 with the ATLAS detector at the CERN Large Hadron Collider. Events with two large-radius jets in the final state, one with transverse momentum $p_{\rm T} > 500$ GeV and a second with $p_{\rm T}>350$ GeV, are used for the measurement. The top-quark candidates are separated from the multijet background using jet substructure information and association with a $b$-tagged jet. The measured spectra are corrected for detector effects to a particle-level fiducial phase space and a parton-level limited phase space, and are compared to several Monte Carlo simulations by means of calculated $\chi^2$ values. The cross-section for $t\bar{t}$ production in the fiducial phase-space region is $292 \pm 7 \ \rm{(stat)} \pm 76 \rm{(syst)}$ fb, to be compared to the theoretical prediction of $384 \pm 36$ fb

Measurements of ttˉt\bar{t} differential cross-sections of highly boosted top quarks decaying to all-hadronic final states in pppp collisions at s=13 \sqrt{s}=13\, TeV using the ATLAS detector

Measurements are made of differential cross-sections of highly boosted pair-produced top quarks as a function of top-quark and $t\bar{t}$ system kinematic observables using proton--proton collisions at a center-of-mass energy of $\sqrt{s} = 13$ TeV. The data set corresponds to an integrated luminosity of $36.1$ fb$^{-1}$, recorded in 2015 and 2016 with the ATLAS detector at the CERN Large Hadron Collider. Events with two large-radius jets in the final state, one with transverse momentum $p_{\rm T} > 500$ GeV and a second with $p_{\rm T}>350$ GeV, are used for the measurement. The top-quark candidates are separated from the multijet background using jet substructure information and association with a $b$-tagged jet. The measured spectra are corrected for detector effects to a particle-level fiducial phase space and a parton-level limited phase space, and are compared to several Monte Carlo simulations by means of calculated $\chi^2$ values. The cross-section for $t\bar{t}$ production in the fiducial phase-space region is $292 \pm 7 \ \rm{(stat)} \pm 76 \rm{(syst)}$ fb, to be compared to the theoretical prediction of $384 \pm 36$ fb